Loading...
Loading...
Tetraphase Pharmaceuticals, Inc.
today announced that it has
presented results from studies that demonstrate efficacy of two
next-generation antibiotic candidates against community-acquired multi-drug
resistant (MDR) infections. These studies – which support the efficacy of the
company's lead candidate, eravacycline, in the treatment of patients with
community-acquired, complicated intra-abdominal infections (cIAIs), as well as
the potential of pre-clinical candidate TP-271's activity against
community-acquired bacterial pneumonia (CABP) – were described in one oral
presentation and two poster presentations at the 23rd European Congress of
Clinical Microbiology and Infectious Disease (ECCMID). The Congress occurs
from April 27 to 30, 2013 in Berlin, Germany.
"These data continue to demonstrate the potential of our antibiotic franchise,
both in terms of our lead candidate eravacycline, and the strength of our
pre-clinical program, " said Guy Macdonald, Tetraphase President and Chief
Executive Officer. "Antibiotic resistance, particularly among the
difficult-to-treat populations with Gram-negative infections, represents a
potential global health crisis. We are pleased by the results that our
compounds display, particularly in the crucial areas of multi-drug resistant,
community-acquired infections.”
The oral presentation, which focused on results from a global Phase 2 trial,
examined eravacycline compared to standard-of-care ertapenem for the treatment
of community-acquired cIAIs. Results showed that eravacycline demonstrated
efficacy in all populations at all study time points when examining both the
microbiological activity of the pathogens and the clinical cure rates. The
findings strongly support the use of eravacycline in the treatment of cIAI,
including those hard-to-treat patients with multi-drug resistant gram-negative
infections.
Following are details for each of Tetraphase's three presentations:
* “Characterization of baseline pathogens and microbiological eradiation in
a phase 2 trial for treatment of complicated intra-abdominal infections
comparing eravacycline (TP-434) to ertapenem.” C. Fyfe, J. Deane, T.
Grossman, P. Horn, G. Moore, D. Sahm, J. Studeny, S. Walpole, and J.
Sutcliffe. Presented as an oral presentation (#277) on Sunday, 28 April
2013 at 12:06 p.m. CEST as part of ECCMID's session on “Clinical trials of
antimicrobial agents”
* “The fluorocycline TP-271 is potent against major complicated
community-acquired bacterial pneumonia (CABP) pathogens.” T. H. Grossman,
C. Fyfe, W. O'Brien, D. E. Low, M. B. Minyard, K. Waites, J. Dubois, J. A.
Sutcliffe. Presented as a poster (# 1641) on Sunday April 28, 2013 from
1:30 – 2:30 p.m. CEST as part of the session “New antibacterial agents
other than beta-lactams.”
* “Time to defervescence as an early marker of clinical response in patients
with complicated intra-abdominal infections treated with eravacycline or
ertapenem.” P. Horn, J. Sutcliffe, S. Walpole. Presented as a poster (#
2107) on Monday, April 29 from 1:30 – 2:30 p.m. CEST as part of the
session “Endocarditis and other serious infections– clinical
observations.”
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in